USPTO Examiner ROSENTHAL ANDREW S - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18629406METHOD AND KIT FOR BOWEL PREPARATIONApril 2024April 2025Allow1210YesNo
18612888CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLESMarch 2024May 2025Allow1400YesNo
18587736EMBOLIC COMPOSITIONSFebruary 2024April 2025Allow1310YesNo
18582320PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATEFebruary 2024June 2025Allow1611NoNo
18529962NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUSDecember 2023August 2024Allow800YesNo
18480331MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITYOctober 2023October 2024Abandon1310NoNo
18244391INTRANASAL DELIVERY OF CANNABIDIOL TO TREAT CENTRAL NERVOUS SYSTEM DISORDERSSeptember 2023November 2024Abandon1420NoYes
18455930METHOD FOR BOWEL PREPARATIONAugust 2023October 2024Allow1320NoNo
18225475FORMULATIONS COMPRISING CYCLOSPORIN AJuly 2023October 2024Abandon1510NoNo
18223252THERAPEUTIC CLAY COMPOSITIONS AND METHODS OF USINGJuly 2023July 2024Allow1210NoNo
18345643COMPOSITIONS AND METHODS RELATED TO RHAMNUS PRINOIDES (GESHO) EXTRACT FOR THE INHIBITION OF POLYMICROBIAL BIOFILM FORMATIONJune 2023April 2025Allow2220YesNo
18332487LIPID NANOPARTICLE FORMULATIONSJune 2023December 2024Allow1811NoNo
18306402PERSONAL CARE PRODUCTS COMPRISING HIGHLY CATIONIC SUBSTITUTED STARCHESApril 2023May 2025Abandon2420NoNo
18188780DOSING WITH AN AZOLOPYRIMIDINE COMPOUNDMarch 2023May 2024Abandon1410NoNo
18187132ANTIMICROBIAL TOPICAL COMPOSITIONS CONTAINING MANUKA OILMarch 2023October 2024Abandon1901NoNo
18185175TRANSDERMAL PATCHMarch 2023April 2024Abandon1301NoNo
18115890Methods of Making CapsulesMarch 2023June 2025Allow2800YesNo
18167123FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENTFebruary 2023March 2024Allow1310YesNo
18100363NANOCRYSTALS, COMPOSITIONS, AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUSJanuary 2023September 2023Allow700YesNo
18089861PAINTING WITH BIOCIDES COMPOSITION AND/OR PROLONGED RELEASE PESTICIDESDecember 2022May 2025Abandon2910NoNo
18007705KINASE INHIBITORSDecember 2022June 2025Allow3000YesNo
18056771INJECTABLE AND INHALABLE FORMULATIONSNovember 2022April 2025Allow2940YesNo
17988890PHOTOSTABILIZING COMPOUNDS, COMPOSITIONS, AND METHODSNovember 2022July 2023Allow800YesNo
17966668INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAMEOctober 2022September 2023Allow1100NoNo
17915952Method for Treating SARS and Treating or Preventing ARDSSeptember 2022May 2025Allow3200YesNo
17896808LEVODOPA FRACTIONATED DOSE COMPOSITION AND USEAugust 2022August 2023Allow1200YesNo
17893716MANUFACTURING METHOD OF HEMOSTATIC MATERIAL AND HEMOSTATIC MATERIAL PREPARED THEREBYAugust 2022February 2025Abandon2920NoNo
17870313LIPID COMPOUND AS WELL AS LIPID CARRIER, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION AND PHARMACEUTICAL PREPARATION CONTAINING SAMEJuly 2022March 2023Allow811NoNo
17864332COMPOSITION AS AUXILIARY MEANS FOR ORAL MEDICATIONJuly 2022March 2024Allow2110NoNo
17849887METHOD AND KIT FOR BOWEL PREPARATIONJune 2022January 2024Allow1820NoNo
17808649HETEROCYCLIC COMPOUNDS AND NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING SAMEJune 2022November 2023Abandon1720NoNo
17784555PHOSPHATE-CONTAINING ANTI-CORROSIVE PIGMENTJune 2022June 2025Allow3600NoNo
17832997SYSTEM AND METHOD FOR THERAPEUTIC COMPOSITIONS FROM A PLURALITY OF DIFFERENT BIRTH TISSUES AND EXOSOMESJune 2022October 2024Allow2911YesNo
17782425PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG BIS(MONOETHANOLAMINE)June 2022May 2025Allow3510NoNo
17824654METHOD OF TREATMENTMay 2022March 2024Allow2210YesNo
17750970PHOTOCHEMICALLY STABLE, NON-LEACHING, BRIDGED POLYSILSESQUIOXANE BASED SUNSCREENSMay 2022March 2025Allow3400YesNo
17744534SYSTEMS AND METHODS FOR PREPARING AND TRANSPORTING AN INJECTABLE SLURRYMay 2022July 2023Abandon1410NoNo
17658288Personal Care Compositions for Treating Odor Causing Bacteria and Methods for the SameApril 2022September 2024Allow3041YesNo
17653575PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORESMarch 2022March 2024Abandon2410NoNo
17753307Composition and Method for treatment of diabetesFebruary 2022February 2025Allow3600NoNo
17621778Oral Care Compositions Comprising Star-Shaped PolymersDecember 2021November 2024Allow3500NoNo
17551550Pharmaceutical Compositions of Dimethyl FumarateDecember 2021January 2024Allow2511NoNo
17616074A POLYMER AND A TOPICAL COMPOSITION COMPRISING THE POLYMERDecember 2021August 2024Allow3300NoNo
17535080CARBON MONOXIDE-BASED THERAPIES AND IMPLANTABLE DEVICES FOR THE TREATMENT OF VASCULAR DISEASENovember 2021March 2024Allow2711YesNo
17535493INJECTABLE SLURRIES AND METHODS OF MANUFACTURING THE SAMENovember 2021May 2022Allow610YesNo
17612468TREATMENT OF SYSTOLIC DYSFUNCTIONNovember 2021January 2025Abandon3710NoNo
17610175BIOACTIVE GLASS COMPOSITIONSNovember 2021June 2025Allow4320YesNo
17599253POLYMER AGENTS FOR CARDIOPULMONARY RESUSCITATIONSeptember 2021March 2025Allow4110YesNo
17598160IMIDAZOQUINOLINE COMPOUNDS AND PRODRUGS THEREOFSeptember 2021December 2024Allow3910NoNo
17469232METHOD FOR LIQUID-TO-SOLID PHASE SEPARATION OF URANIUM AND URANYL CONTAMINANT FROM VARIOUS SOLUTIONSSeptember 2021March 2025Abandon4221NoNo
17464256SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTYSeptember 2021June 2023Abandon2210NoNo
17464268SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTYSeptember 2021January 2024Abandon2820NoNo
17435110INDUCING CASPASE ACTIVITYAugust 2021November 2024Allow3920NoNo
17400957COMPOSITIONS COMPRISING PGI2-RECEPTOR AGONISTS AND PROCESSES FOR THE PREPARATION THEREOFAugust 2021July 2023Allow2310NoNo
17443743FRAGRANCE COMPOSITIONJuly 2021April 2025Abandon4541YesNo
17384629COMPOSITION AND METHOD FOR REDUCING THE INFECTIVITY AND VIRUCIDAL ACTIVITY OF SARS-COV-2July 2021August 2023Abandon2510NoNo
17378083CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLESJuly 2021December 2023Allow2911YesNo
17423377METHOD FOR ORAL CAVITY CAREJuly 2021March 2025Abandon4420NoNo
17376237COMPOSITION FOR A FORMULATED ORAL PREBIOTIC EDIBLE COMPOSITIONJuly 2021September 2023Allow2710YesNo
17366620EMBOLIC COMPOSITIONSJuly 2021October 2023Allow2810NoNo
17418940ADAMANTANECARBOXYLIC ACID BENZYL AMIDE DERIVATIVE COMPOUND AND SKIN WHITENING COMPOSITION COMPRISING SAMEJune 2021May 2024Allow3420YesNo
17304562CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGSJune 2021June 2023Abandon2410NoNo
17356131KITS FOR TREATING THE HAIRJune 2021July 2023Abandon2510NoNo
17304494STABILIZED HYPOCHLOROUS ACID SOLUTION AND METHOD FOR STABILIZING HYPOCHLOROUS ACID FOR LONGER SHELF LIFEJune 2021July 2024Abandon3720NoNo
17416309SOLID COSMETIC COMPOSITION CONTAINING VEGETABLE BUTTERSJune 2021September 2024Allow3921NoNo
17342983METHOD FOR BOWEL PREPARATIONJune 2021May 2023Allow2310NoNo
17338982VIRUCIDAL COMPOSITIONS AND METHODSJune 2021February 2024Abandon3211NoNo
17299697MULTICOMPONENT IN SITU COLORATION COMPOSITIONJune 2021January 2025Allow4410NoNo
17332704SYNTHETIC MELANIN NANOPARTICLES AND USES THEREOFMay 2021May 2024Allow3611YesNo
17317517NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDSMay 2021January 2023Allow2000YesNo
17256979COMPLEX FOR ENHANCING IMMUNE RESPONSEMay 2021August 2024Allow4310YesNo
17291717COSMETIC COMPOSITION COMPRISING A POLYHYDROXYALKANOATE IN AN OILY MEDIUMMay 2021November 2024Allow4210NoNo
17288173BIOENERGETIC NICOTINIC ACID GLYCEROL ESTERS, COMPOSITIONS AND METHODS OF USING SAMEApril 2021June 2023Allow2500YesNo
17236848METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USEApril 2021November 2022Allow1900YesNo
17236861METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USEApril 2021February 2023Allow2200YesNo
17236839METHOD FOR PRODUCING A NANOSTRUCTURED COMPLEX (CFI-1), A PROTEIN-ASSOCIATED NANOSTRUCTURED COMPLEX (MRB-CFI-1) AND USEApril 2021November 2022Allow1900YesNo
17230175IMMUNOSUPPRESSANT FORMULATIONSApril 2021April 2024Allow3630NoNo
17228753PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE THEREOFApril 2021July 2024Allow3940YesNo
17219915HYDROGEL COMPOSITION WITH THERMOS-SENSITIVE AND IONIC REVERSIBLE PROPERTIES, CARRIER, METHOD FOR PREPARING AND METHOD OF USE THEREOFApril 2021November 2023Allow3121YesNo
17219253LEVODOPA FRACTIONATED DOSE COMPOSITION AND USEMarch 2021May 2022Allow1320YesNo
17256980METHODS FOR PREPARING COMPLEX FOR ENHANCING IMMUNE RESPONSEMarch 2021October 2024Allow4611NoNo
17206822Debridement CompositionMarch 2021April 2025Allow4821NoNo
17203403PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOLMarch 2021May 2023Abandon2610NoNo
17188359INJECTABLE SLURRIES AND METHODS OF MANUFACTURING AND USING THE SAMEMarch 2021November 2023Allow3320NoNo
17269912MICROCAPSULE-BASED VACCINEFebruary 2021March 2025Allow4821YesNo
17268281AN OILY COMPOSITIONFebruary 2021May 2024Abandon3910NoNo
17173400MELTING MASSAGE BARFebruary 2021December 2023Allow3440NoNo
17171060NOVEL NANOPARTICLES USING ANIONIC POLYMER, PREPARATION METHOD AND COMPOSITION THEREOFFebruary 2021April 2023Allow2601YesNo
17154516Phenylephrine Hydrochloride Compositions and ContainersJanuary 2021April 2022Allow1481YesYes
17262198LYCOPENE COMPOSITIONS AND METHODS FOR PROTECTING SKIN AGAINST ULTRAVIOLET RADIATIONJanuary 2021August 2024Abandon4341YesNo
17151093Composition, Method of Making, Method of Use and System for Hair HealthJanuary 2021March 2023Abandon2601NoNo
17145999Esterquat CompositionsJanuary 2021May 2024Allow4010NoNo
17145086METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORSJanuary 2021July 2023Allow3010NoNo
17144877LABELED SILICA-COATED GOLD NANORODS AND A METHOD FOR PRODUCING THE SAMEJanuary 2021January 2025Abandon4821NoNo
17144033FORMULATIONS COMPRISING CYCLOSPORIN AJanuary 2021August 2023Abandon3210NoNo
17257159METHOD FOR PREPARING ORGANIC-INORGANIC HYBRID MICROCAPSULEDecember 2020January 2024Allow3710YesNo
17254182PHOTOSTABILIZING COMPOUNDS, COMPOSITIONS, AND METHODSDecember 2020August 2022Allow2010NoNo
17253577OSCILLATORY GELSDecember 2020July 2024Allow4321YesNo
17123313FIBER CONTAINING HAIR STYLING COMPOSITIONDecember 2020December 2022Allow2410YesNo
17252782Use of Apoptotic Compensatory Proliferation Signaling Vesicles in Tissue Repair and Wound HealingDecember 2020April 2024Allow4011YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROSENTHAL, ANDREW S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
33
Examiner Affirmed
25
(75.8%)
Examiner Reversed
8
(24.2%)
Reversal Percentile
36.3%
Lower than average

What This Means

With a 24.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
108
Allowed After Appeal Filing
16
(14.8%)
Not Allowed After Appeal Filing
92
(85.2%)
Filing Benefit Percentile
15.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ROSENTHAL, ANDREW S - Prosecution Strategy Guide

Executive Summary

Examiner ROSENTHAL, ANDREW S works in Art Unit 1613 and has examined 683 patent applications in our dataset. With an allowance rate of 54.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner ROSENTHAL, ANDREW S's allowance rate of 54.0% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ROSENTHAL, ANDREW S receive 2.43 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROSENTHAL, ANDREW S is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +45.2% benefit to allowance rate for applications examined by ROSENTHAL, ANDREW S. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 15.1% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 21.1% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 60.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 48.4% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 58.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 83.2% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 54% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.